Trials / Unknown
UnknownNCT05825196
Study of Serum Tumor Markers of HBV Associated HCC
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 164 (estimated)
- Sponsor
- Qianfoshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
In this study, the investigators will detect the expression of four potential HBV-related HCC biomarkers: PGIR,FAM3C,LAMB1 and SDC4 in tumor tissues and peripheral blood, to explore the specific molecular markers for the early diagnosis of HBV-related HCC.
Detailed description
Paired hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and adjacent liver tissues were selected, and the mRNA and protein expressions of the PGIR,FAM3C,LAMB1 and SDC4 biomarkers in tissues were detected by RT-PCR, western Blot and immunohistochemical analysis. At the same time, healthy subjects were selected as the control group, and mRNA and protein expression levels of the above molecules in blood were detected by RT-PCR and ELISA. At the same time, the correlation between the above biomarkers and the clinical data of patients, such as diagnosis, pathological grading, recurrence, metastasis and survival time was statistically analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | tumor tissue and blood tests | In this study, we need to collect an extra tube of blood for routine testing and the tissue after completion of pathological examination. |
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2025-01-31
- Completion
- 2025-12-31
- First posted
- 2023-04-24
- Last updated
- 2023-04-24
Source: ClinicalTrials.gov record NCT05825196. Inclusion in this directory is not an endorsement.